122 related articles for article (PubMed ID: 8756510)
1. Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3 dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain.
Mosberg HI; Dua RK; Pogozheva ID; Lomize AL
Biopolymers; 1996 Sep; 39(3):287-96. PubMed ID: 8756510
[TBL] [Abstract][Full Text] [Related]
2. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
Mosberg HI; Omnaas JR; Lomize A; Heyl DL; Nordan I; Mousigian C; Davis P; Porreca F
J Med Chem; 1994 Dec; 37(25):4384-91. PubMed ID: 7996550
[TBL] [Abstract][Full Text] [Related]
3. Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
Mosberg HI; Lomize AL; Wang C; Kroona H; Heyl DL; Sobczyk-Kojiro K; Ma W; Mousigian C; Porreca F
J Med Chem; 1994 Dec; 37(25):4371-83. PubMed ID: 7996549
[TBL] [Abstract][Full Text] [Related]
4. Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands.
Lomize AL; Pogozheva ID; Mosberg HI
Biopolymers; 1996 Feb; 38(2):221-34. PubMed ID: 8589255
[TBL] [Abstract][Full Text] [Related]
5. Complementarity of delta opioid ligand pharmacophore and receptor models.
Mosberg HI
Biopolymers; 1999; 51(6):426-39. PubMed ID: 10797231
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of opioid ligand-receptor interaction models: the structural basis of mu vs delta selectivity.
Mosberg HI; Fowler CB
J Pept Res; 2002 Dec; 60(6):329-35. PubMed ID: 12464111
[TBL] [Abstract][Full Text] [Related]
7. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the delta-selective opioid peptide deltorphin I: effects on binding affinity and selectivity.
Heyl DL; Schmitter SJ; Bouzit H; Johnson TW; Hepp AM; Kurtz KR; Mousigian C
Int J Pept Protein Res; 1994 Nov; 44(5):420-6. PubMed ID: 7896499
[TBL] [Abstract][Full Text] [Related]
8. N-methylated cyclic enkephalin analogues retain high opioid receptor binding affinity.
Weltrowska G; Berezowska I; Lemieux C; Chung NN; Wilkes BC; Schiller PW
Chem Biol Drug Des; 2010 Feb; 75(2):182-8. PubMed ID: 20028398
[TBL] [Abstract][Full Text] [Related]
9. The mu- and delta-opioid pharmacophore conformations of cyclic beta-casomorphin analogues indicate docking of the Phe3 residue to different domains of the opioid receptors.
Brandt W; Stoldt M; Schinke H
J Comput Aided Mol Des; 1996 Jun; 10(3):201-12. PubMed ID: 8808737
[TBL] [Abstract][Full Text] [Related]
10. Modification of the Phe3 aromatic moiety in delta receptor-selective dermorphin/deltorphin-related tetrapeptides. Effects on opioid receptor binding.
Heyl DL; Mosberg HI
Int J Pept Protein Res; 1992 May; 39(5):450-7. PubMed ID: 1330964
[TBL] [Abstract][Full Text] [Related]
11. Conformationally restricted deltorphin analogues.
Schiller PW; Weltrowska G; Nguyen TM; Wilkes BC; Chung NN; Lemieux C
J Med Chem; 1992 Oct; 35(21):3956-61. PubMed ID: 1331451
[TBL] [Abstract][Full Text] [Related]
12. Conformational studies of stereoisomeric 14-membered cyclic enkephalin analogues containing 1-naphthylalanine at the fourth position: chirality effect of leucine at the fifth position on biological activity and receptor selectivity.
Yamazaki T; Said-Nejad OE; Schiller PW; Goodman M
Biopolymers; 1991 Jun; 31(7):877-98. PubMed ID: 1655089
[TBL] [Abstract][Full Text] [Related]
13. Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Marsden BJ; Wilkes BC
J Med Chem; 1991 Oct; 34(10):3125-32. PubMed ID: 1656045
[TBL] [Abstract][Full Text] [Related]
14. Conformational features responsible for the binding of cyclic analogues of enkephalin to opioid receptors. III. Probable binding conformations of mu-agonists with phenylalanine in position 3.
Shenderovich MD; Nikiforovich GV; Golbraikh AA
Int J Pept Protein Res; 1991 Apr; 37(4):241-51. PubMed ID: 1654306
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study.
Gao P
J Comput Aided Mol Des; 1996 Aug; 10(4):327-36. PubMed ID: 8877704
[TBL] [Abstract][Full Text] [Related]
16. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.
Schiller PW; Nguyen TM; Weltrowska G; Wilkes BC; Marsden BJ; Lemieux C; Chung NN
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11871-5. PubMed ID: 1334552
[TBL] [Abstract][Full Text] [Related]
17. Conformational restriction of Tyr and Phe side chains in opioid peptides: information about preferred and bioactive side-chain topology.
Tourwé D; Verschueren K; Frycia A; Davis P; Porreca F; Hruby VJ; Toth G; Jaspers H; Verheyden P; Van Binst G
Biopolymers; 1996 Jan; 38(1):1-12. PubMed ID: 8679939
[TBL] [Abstract][Full Text] [Related]
18. Ring substituted and other conformationally constrained tyrosine analogues of [D-Pen2,D-Pen5]enkephalin with delta opioid receptor selectivity.
Toth G; Russell KC; Landis G; Kramer TH; Fang L; Knapp R; Davis P; Burks TF; Yamamura HI; Hruby VJ
J Med Chem; 1992 Jun; 35(13):2384-91. PubMed ID: 1320122
[TBL] [Abstract][Full Text] [Related]
19. Opioid receptor affinity and selectivity effects of second residue and carboxy terminal residue variation in a cyclic disulfide-containing opioid tetrapeptide.
Heyl DL; Omnaas JR; Sobczyk-Kojiro K; Medzihradsky F; Smith CB; Mosberg HI
Int J Pept Protein Res; 1991 Mar; 37(3):224-9. PubMed ID: 1651290
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the bioactive form of linear peptide antagonists at the omega-opioid receptor.
Chao TM; Perez JJ; Loew GH
Biopolymers; 1996 Jun; 38(6):759-68. PubMed ID: 8652796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
